| Literature DB >> 24900282 |
Stephen Hanessian1, Alexandre Giguère1, Justyna Grzyb1, Juan Pablo Maianti1, Oscar M Saavedra1, James B Aggen2, Martin S Linsell2, Adam A Goldblum2, Darin J Hildebrandt2, Timothy R Kane2, Paola Dozzo2, Micah J Gliedt2, Rowena D Matias2, Lee Ann Feeney2, Eliana S Armstrong2.
Abstract
Deoxygenation of the diol groups in rings A and D of neomycin in combination with the introduction of an N1-(l)-HABA group in the 2-deoxystreptamine subunit (ring B) leads to a novel and potent antibiotic (1) with activity against strains of S. aureus carrying known aminoglycoside resistance determinants, as well as against an extended panel of Methicillin-resistant S. aureus isolates (n = 50). Antibiotic 1 displayed >64 fold improvement in MIC50 and MIC90 against this MRSA collection when compared to the clinically relevant aminoglycosides amikacin and gentamicin. The synthesis was achieved in six steps and 15% overall yield.Entities:
Keywords: Aminoglycoside; MRSA; antibiotics; deoxygenation; enzymatic modification; neomycin analogues; resistance
Year: 2011 PMID: 24900282 PMCID: PMC4018147 DOI: 10.1021/ml200202y
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345